Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Baudax Bio Inc BXRXQ

Healthcare
Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in... see more

Recent & Breaking News (PINL:BXRXQ)

Baudax Bio Announces Corporate Update

GlobeNewswire October 18, 2023

Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors

GlobeNewswire September 28, 2023

Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference

GlobeNewswire September 7, 2023

Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

GlobeNewswire August 23, 2023

Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

GlobeNewswire August 17, 2023

Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 16, 2023

Baudax Bio Acquires TeraImmune, Inc.

GlobeNewswire June 30, 2023

Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000

GlobeNewswire June 7, 2023

Baudax Bio Announces Date of Reconvened Annual Meeting

GlobeNewswire June 6, 2023

Baudax Bio Reports First Quarter Financial Results and Provides Business Update

GlobeNewswire May 12, 2023

Baudax Bio to Present at the Sidoti Virtual Investor Conference

GlobeNewswire May 3, 2023

Baudax Bio Announces Closing of $4 Million Public Offering

GlobeNewswire May 1, 2023

Baudax Bio Announces Pricing of $4 Million Public Offering

GlobeNewswire April 26, 2023

Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000

GlobeNewswire April 25, 2023

Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 Trial

GlobeNewswire April 24, 2023

Baudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000

GlobeNewswire March 27, 2023

Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update

GlobeNewswire February 23, 2023

Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000

GlobeNewswire January 24, 2023

Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery

GlobeNewswire December 8, 2022

Baudax Bio Announces Closing of $5 Million Public Offering

GlobeNewswire December 6, 2022